ID

33105

Descripción

Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B

Palabras clave

Versiones (1)
  1. 28/11/18 28/11/18 -
Titular de derechos de autor

GSK group of companies

Subido en

28 de noviembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021

Inglés

Elimination Criteria (Study Eligibility)

1 formularios  
Elimination Criteria during the Study
Descripción

Elimination Criteria during the Study

Check below "Yes" for all that apply
Descripción

The following criteria should be checked at each visit subsequent to the first visit. If any become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol analysis

Tipo de datos

text

A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Descripción

A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.

Tipo de datos

boolean

B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
Descripción

For corticosteroids, this mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed

Tipo de datos

boolean

C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
Descripción

C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.

Tipo de datos

boolean

D. Administration of immunoglobulins and/or any blood products during the study period.
Descripción

D. Administration of immunoglobulins and/or any blood products during the study period.

Tipo de datos

boolean

Volver a la parte superior de la página

Similar models

Elimination Criteria (Study Eligibility)

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Elimination Criteria during the Study
Check below "Yes" for all that apply
Item
Check below "Yes" for all that apply
text
A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Item
A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
Item
B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
boolean
C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
Item
C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
boolean
D. Administration of immunoglobulins and/or any blood products during the study period.
Item
D. Administration of immunoglobulins and/or any blood products during the study period.
boolean
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial